A careful reassessment of anthracycline use in curable breast cancer
Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of...
Enregistré dans:
Auteurs principaux: | Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/aad7894979b94db08a790483d6338a18 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cardiac and skeletal muscle predictors of impaired cardiorespiratory fitness post-anthracycline chemotherapy for breast cancer
par: Amy A. Kirkham, et autres
Publié: (2021) -
Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
par: Li-Yan Zhou, et autres
Publié: (2015) -
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
par: Jason J Zoeller, et autres
Publié: (2021) -
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
par: Craig Davison, et autres
Publié: (2021) -
Genetic basis of anthracyclines cardiotoxicity: Literature review
par: M. Yu. Sinitsky, et autres
Publié: (2021)